Cyril Amarchand Mangaldas (CAM) has advised Novo Tellus Capital Partners, an existing shareholder of Tessolve Semiconductor Private Limited, in connection with Vector Line Capital’s $75 million investment in the semiconductor engineering services company.
The mandate concerns Hero Electronix-backed Tessolve and places CAM on the existing shareholder’s side of the transaction. The team was led by Abhishek Kalra, Partner, with strategic guidance from Aditi Manchanda, Partner, and support from Kaushik Raichura, Senior Associate.
The transaction marks CAM’s third reported advisory engagement for Novo Tellus involving Tessolve. The firm previously advised on Novo Tellus’s approximately $40 million initial investment in 2021 and in connection with TPG’s approximately $150 million investment in the company in 2025.
The latest disclosure identifies the investor, investment amount, existing shareholder and legal team, but does not set out the ownership percentage involved, the transaction structure or the contractual rights negotiated. Those distinctions matter when assessing what an investment means for a company and its existing shareholders.
Key Highlights
Investment: Vector Line Capital is investing $75 million in Tessolve, a Hero Electronix-backed semiconductor engineering services company.
Client represented: CAM advised existing shareholder Novo Tellus Capital Partners, rather than the incoming investor.
Continuing mandate: CAM previously advised Novo Tellus on its approximately $40 million initial investment in 2021 and in connection with TPG’s approximately $150 million investment in 2025.
Transaction team: Abhishek Kalra led the team, with strategic guidance from Aditi Manchanda and support from Kaushik Raichura.
Terms not disclosed: The announcement does not specify valuation, stake size, primary or secondary components, or completion conditions.
Vector Line Capital invests $75 million in Hero Electronix-backed Tessolve
Vector Line Capital’s $75 million investment is the latest Tessolve transaction identified in the disclosure of CAM’s work for Novo Tellus. Tessolve is described as a semiconductor engineering services company backed by Hero Electronix. The announcement does not quantify Hero Electronix’s holding or describe its governance role.
The transaction description identifies both the investment amount and CAM’s client:
“Cyril Amarchand Mangaldas advised Novo Tellus Capital Partners (“Novo Tellus”), an existing shareholder of Tessolve Semiconductor Private Limited (“Tessolve”), a Hero Electronix-backed semiconductor engineering services company, in connection with Vector Line Capital ’s USD 75 million investment in Tessolve.”
An investment amount is not, by itself, a statement of enterprise value or equity valuation. Nor does it establish whether the entire consideration will reach the company through newly issued securities, be paid to selling shareholders, or be divided between primary and secondary components. The disclosed material does not resolve those questions.
That distinction has legal and commercial consequences. A primary issuance can alter the company’s share capital and dilute existing holdings, while a secondary transfer changes ownership of existing securities. A combined transaction can involve both effects. The announcement does not identify which structure applies here and does not provide a separate signing or completion timetable.
Cyril Amarchand Mangaldas advises existing shareholder Novo Tellus
CAM’s disclosed role was to advise Novo Tellus Capital Partners as an existing Tessolve shareholder. This is narrower than a mandate to represent Tessolve or Vector Line Capital. The announcement does not identify counsel for either the company or the incoming investor, and CAM’s engagement should not be read as extending to those parties.
An existing shareholder’s position in an investment transaction can differ from that of both the company and a new investor. Depending on the governing documents, its concerns may include dilution, continued participation rights, governance arrangements, transfer restrictions, and the treatment of rights negotiated in earlier rounds. None of those particular rights is confirmed in this transaction.
Existing shareholder advice can also involve examining how a proposed investment interacts with earlier contractual arrangements. Matters such as consent requirements, amendments to shareholder documents and the continued operation of reserved matters may be relevant, depending on the rights already in place and the structure proposed.
These are general features of private investment work, not a description of undisclosed negotiations in this deal. The announcement does not identify a shareholder disagreement, waiver, negotiated concession or sale by Novo Tellus. In particular, advising an existing shareholder does not establish that the shareholder has exited or reduced its investment.
Tessolve's semiconductor engineering services business
Tessolve’s business is described in the disclosed material as semiconductor engineering services. That description identifies the sector in which it operates, but does not supply a detailed account of its service lines, customer relationships, geographic presence, workforce or financial performance. It also does not establish that Tessolve operates a semiconductor fabrication facility.
The distinction matters because engineering services and semiconductor manufacturing can present different operating models and investment considerations. For an engineering services business, contractual relationships, technical capabilities, intellectual property and personnel can be significant diligence subjects. The announcement, however, does not identify the diligence undertaken or any findings concerning Tessolve.
In this sector generally, legal review may examine ownership of work product, licences to use technology, confidentiality obligations and the allocation of responsibility under customer contracts. The relevance of any particular issue depends on the services supplied and the contractual arrangements involved. There is no disclosed basis to attribute any specific issue to this transaction.
The description of Tessolve as Hero Electronix-backed supplies another part of its corporate context, but not a complete ownership picture. Without a disclosed capitalisation table, the investment cannot be used to calculate the relative holdings of Hero Electronix, Novo Tellus, Vector Line Capital or any other shareholder.
CAM's earlier work for Novo Tellus on Tessolve investments
The current engagement follows two earlier Tessolve-related mandates for the same client. CAM advised Novo Tellus on its approximately $40 million initial investment in 2021 and subsequently advised it in connection with TPG’s approximately $150 million investment in 2025. Together, these disclosures establish a continuing advisory relationship across separate transactions.
The announcement records that history in these terms:
“Cyril Amarchand Mangaldas had previously also advised Novo Tellus on its ~USD 40 million initial investment in Tessolve in 2021 and in connection with TPG’s ~USD 150 million investment in Tessolve in 2025.”
Repeat mandates can give counsel familiarity with an investment’s contractual history. In general, earlier subscription and shareholder arrangements provide the starting point for understanding how a later investment may affect existing rights. Whether those documents remain unchanged, require amendments or are replaced depends on the terms of the subsequent transaction.
The disclosure does not describe the scope of CAM’s earlier work beyond identifying the client, transaction amounts and years. It also does not state whether the lawyers named on the present mandate worked on those earlier transactions. The continuity established here is therefore at the firm-client level, rather than a confirmed account of an unchanged transaction team.
From Novo Tellus's 2021 investment to TPG's 2025 deal
The disclosed chronology begins with Novo Tellus’s approximately $40 million initial investment in Tessolve in 2021. The word “initial” identifies the entry investment referred to in the announcement; it does not establish whether Novo Tellus made additional investments thereafter or how its percentage holding changed over time.
The next identified transaction is TPG’s approximately $150 million investment in 2025. CAM’s role in that transaction was again described by reference to its representation of Novo Tellus. The source does not state that CAM represented TPG, nor does it describe whether the investment involved new shares, existing shares or both.
The latest disclosure, published on 31 October 2026, concerns Vector Line Capital’s $75 million investment. The three figures relate to separate transactions involving different named investors. They should not be treated as a single financing round, or added together and described as fresh capital received by Tessolve without knowing the structure of each transaction.
Equally, the amounts do not demonstrate a valuation trajectory. A larger investment in one year and a smaller investment in another can reflect different stake sizes, instruments or transaction components. What the chronology does establish is that Novo Tellus’s investment has been followed by further disclosed investor activity in Tessolve, with CAM advising Novo Tellus across all three identified events.
Abhishek Kalra leads the transaction team
Abhishek Kalra, Partner, led CAM’s team on the latest mandate. His leadership role is expressly identified in the announcement, which distinguishes it from the strategic guidance provided by Aditi Manchanda and the support provided by Kaushik Raichura.
The announcement states:
“The transaction team was led by Abhishek Kalra, Partner; with strategic guidance from Aditi Manchanda, Partner; and with support from Kaushik Raichura, Senior Associate.”
In a private investment mandate, the lead lawyer’s work may encompass coordinating advice, overseeing negotiations and ensuring that the client’s commercial instructions are reflected in the transaction documents. Where the client is an existing shareholder, the exercise can include considering the interaction between the proposed investment and previously negotiated rights. The announcement does not itemise Kalra’s responsibilities.
The legal framework for an investment also depends on its structure. Corporate authorisations, securities issuance or transfer requirements, and any applicable foreign investment or competition requirements need to be assessed against the actual facts. The disclosure does not identify any particular regulatory approval, filing or exemption, and none can be inferred merely from the announced investment amount.
Aditi Manchanda and Kaushik Raichura support the advisory
Aditi Manchanda, Partner, provided strategic guidance to the transaction team, while Kaushik Raichura, Senior Associate, supported the advisory. These are the roles attributed to them in the announcement. No additional team members, specialist workstreams or external advisers are identified.
The distinction between leadership, strategic guidance and support records how the mandate was staffed, but does not disclose the internal allocation of drafting, negotiations or diligence. It would therefore be inaccurate to assign either lawyer a particular document, regulatory application or negotiated provision that the announcement does not mention.
The same limit applies to the deal’s next steps. The disclosed material does not set out conditions precedent, a closing deadline, post-investment governance arrangements or a proposed use of proceeds. Without those details, the announcement supports a report of the investment and legal mandate, rather than a conclusion that every contractual or regulatory step has been completed.
Legal representation: Cyril Amarchand Mangaldas advised Novo Tellus Capital Partners in connection with Vector Line Capital’s $75 million investment in Tessolve. The team was led by Partner Abhishek Kalra, with strategic guidance from Partner Aditi Manchanda and support from Senior Associate Kaushik Raichura.
Sources
